Cholinesterase Inhibitors
"Cholinesterase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.
| Descriptor ID |
D002800
|
| MeSH Number(s) |
D27.505.519.389.275 D27.505.519.625.120.300 D27.505.696.577.120.300
|
| Concept/Terms |
Cholinesterase Inhibitors- Cholinesterase Inhibitors
- Inhibitors, Cholinesterase
- Anticholinesterase Drugs
- Drugs, Anticholinesterase
- Anticholinesterases
- Anticholinesterase Agents
- Agents, Anticholinesterase
- Anti-Cholinesterases
- Anti Cholinesterases
|
Below are MeSH descriptors whose meaning is more general than "Cholinesterase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Cholinesterase Inhibitors".
This graph shows the total number of publications written about "Cholinesterase Inhibitors" by people in this website by year, and whether "Cholinesterase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 9 | 3 | 12 |
| 2018 | 13 | 3 | 16 |
| 2019 | 8 | 1 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Cholinesterase Inhibitors" by people in Profiles.
-
Myasthenia gravis associated with novel coronavirus 2019 infection: A report of three cases. Clin Neurol Neurosurg. 2021 Sep; 208:106834.
-
Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. Contemp Clin Trials. 2021 08; 107:106488.
-
Molecular modeling-guided optimization of acetylcholinesterase reactivators: A proof for reactivation of covalently inhibited targets. Eur J Med Chem. 2021 Apr 05; 215:113286.
-
A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol. BMC Infect Dis. 2020 Oct 16; 20(1):765.
-
COVID-19 induced ARDS, and the use of galantamine to activate the cholinergic anti-inflammatory pathway. Med Hypotheses. 2020 12; 145:110331.
-
De Novo Drug Design of Targeted Chemical Libraries Based on Artificial Intelligence and Pair-Based Multiobjective Optimization. J Chem Inf Model. 2020 10 26; 60(10):4582-4593.
-
Myasthenic Syndrome Caused by Hydroxychloroquine Used for COVID-19 Prophylaxis. J Clin Neuromuscul Dis. 2020 Sep; 22(1):60-62.
-
COVID-19 and generalized Myasthenia Gravis exacerbation: A case report. Clin Neurol Neurosurg. 2020 09; 196:106045.
-
Design, Synthesis, and Cholinesterase Inhibition Assay of Coumarin-3-carboxamide-N-morpholine Hybrids as New Anti-Alzheimer Agents. Chem Biodivers. 2019 Jul; 16(7):e1900144.
-
Structure-based virtual screening leading to discovery of highly selective butyrylcholinesterase inhibitors with solanaceous alkaloid scaffolds. Chem Biol Interact. 2019 Aug 01; 308:372-376.